The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.

ABSTRACT:

Background

In recent years, new drug development on lung cancer is in full swing in China. The aim of this study was to overview the changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.

Methods

We analysed anti-lung cancer drug clinical trials registered on three websites including the China National Medical Products Administration Centre for Drug Evaluation platform, the Chinese Clinical Trial Registry and ClinicalTrials.gov.

Findings

A total of 1595 anti-lung cancer drug clinical trials from Jan 1st, 2005 to Dec 31st, 2020 were extracted, which included 630 (39•5%) investigator-initiated trials (IITs), 698 (43•8%) domestic industry-sponsored trials (ISTs), and 267 (16•7%) international ISTs. During the past 16 years, the n

SUBMITTER: Zhong Q 

PROVIDER: S-EPMC8315452 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature